Welcome to our dedicated page for Health Catalyst SEC filings (Ticker: HCAT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Locating the story behind Health Catalyst’s adaptive data platform inside a 300-page filing can feel overwhelming. Revenue split between Technology subscriptions and Professional Services, HIPAA risk factors, and contract backlog all sit deep in footnotes—yet they drive valuation. If you have ever asked, “Where can I find the Health Catalyst quarterly earnings report 10-Q filing?” or searched for “Health Catalyst insider trading Form 4 transactions,” this page removes the friction.
Stock Titan’s AI reads every submission the instant it hits EDGAR and surfaces exactly what matters. Our tool converts a dense Health Catalyst annual report 10-K simplified into plain language, flags new 8-K material events explained, and delivers Health Catalyst Form 4 insider transactions real-time so you spot executive stock moves without parsing tables. Need context on incentive plans? The Health Catalyst proxy statement executive compensation section is summarized alongside key metrics. You will also find links to each Health Catalyst earnings report filing analysis, plus guidance for understanding Health Catalyst SEC documents with AI if you are new to regulatory language.
Whether you are monitoring segment margin trends, tracking Health Catalyst executive stock transactions Form 4, or comparing sequential growth across hospitals served, every disclosure type—from 10-Q updates to 8-K contract wins—is here with real-time alerts. Analysts use these insights to model recurring revenue, portfolio managers watch insider buys for conviction signals, and healthcare strategists examine risk factor evolution. Explore the complete library now and see Health Catalyst SEC filings explained simply—so your next decision starts with clarity, not complexity.
Health Catalyst, Inc. (HCAT) reporting officer Jason Alger, the company's Chief Financial Officer, reported a mandatory sale of common stock to satisfy tax withholding from vested restricted stock units. The Form 4 shows a disposition of 2,613 shares on 09/02/2025 at a reported price of $3.3627 per share, leaving the reporting person with 267,033 shares beneficially owned after the transaction. The filing was submitted as an individual Form 4 and signed on behalf of the reporting person by an attorney-in-fact on 09/04/2025. The filing clarifies this was a non-discretionary "sell to cover" required by the issuer's equity plan and not an independent trading decision.
Daniel LeSueur, Chief Operating Officer of Health Catalyst, Inc. (HCAT), reported a sale of 3,663 shares of the issuer's common stock on 09/02/2025 at a price of $3.3627 per share. The filing states this sale was a mandatory "sell to cover" to satisfy tax-withholding obligations arising from the vesting of restricted stock units and not a discretionary trade. After the transaction, the reporting person beneficially owned 198,367 shares. The Form 4 was signed by Benjamin Landry as attorney-in-fact on 09/04/2025. The report documents an insider compliance action rather than an open-market decision.
Burton D. Burton, Chief Executive Officer and Director of Health Catalyst, Inc. (HCAT), reported a non-discretionary sell-to-cover transaction on 09/02/2025. The filing shows 8,335 shares were sold at $3.3627 per share to satisfy tax withholding obligations arising from vested restricted stock units; this was a mandatory sale under the issuer's equity plan rather than a voluntary trade. After the transaction the reporting person beneficially owns 1,448,814 shares. No derivative securities were reported in this filing and the Form 4 was signed by an attorney-in-fact on 09/04/2025.
Health Catalyst insider sale tied to RSU tax withholding. Chief People Officer Linda Llewelyn reported a sale of 2,854 shares of Health Catalyst, Inc. (HCAT) on 09/02/2025 at $3.3627 per share. The filing states this sale was a mandated "sell-to-cover" to satisfy tax withholding on vested restricted stock units, not a discretionary trade. After the transaction, the reporting person beneficially owned 153,025 shares. The Form 4 was signed by an attorney-in-fact on 09/04/2025.
Benjamin Landry, General Counsel of Health Catalyst, Inc. (HCAT), reported a non-discretionary sale of 3,138 shares of common stock on 09/02/2025 at a price of $3.3627 per share to satisfy tax withholding from the vesting of restricted stock units. After the transaction, he beneficially owned 147,987 shares. The filing specifies this was a sell-to-cover required under the issuer's equity incentive plan and not a voluntary trade by the reporting person. The Form 4 is signed and dated 09/04/2025.
Health Catalyst, Inc. director Spencer Justin was granted 68,572 restricted stock units (RSUs) on 09/01/2025 under the company's 2019 Stock Option and Incentive Plan. Each RSU represents a contingent right to one share of common stock and the award was reported with a $0.00 per-share price, consistent with typical equity awards to directors.
The RSUs vest under the Non-Employee Director Compensation Policy: 33.33% vests on 09/01/2026 and the remaining 66.67% vests in two equal annual installments thereafter. The filing was made by one reporting person and signed by an attorney-in-fact on 09/03/2025.
Health Catalyst, Inc. (HCAT) Form 144 notice reports a proposed sale of 2,854 common shares with an aggregate market value of $9,597.15, to be sold through Morgan Stanley Smith Barney LLC on 09/02/2025 on NASDAQ. The shares were acquired on 09/02/2025 as restricted stock from Health Catalyst, Inc. and were granted as compensation. The filer represents they are not aware of undisclosed material adverse information. The filing also discloses a prior sale by Linda Llewelyn of 2,965 restricted shares on 06/02/2025 for gross proceeds of $10,777.18.
Health Catalyst, Inc. Form 144 summary: This notice reports a proposed sale of 4,578 shares of common stock through Morgan Stanley Smith Barney LLC on 09/02/2025 with an aggregate market value of $15,394.44. The filing shows the shares were acquired as restricted stock from Health Catalyst, Inc. on 09/02/2025 as compensation. The filer previously sold 4,747 restricted shares on 06/02/2025 for gross proceeds of $17,254.40. The issuer's outstanding shares are listed as 70,373,625. Some filer identification fields (CIK/CCC and contact details) are not provided in the visible content.
Health Catalyst, Inc. (HCAT) Form 144 summary: This notice reports a proposed sale of 3,138 restricted common shares through Morgan Stanley Smith Barney on 09/02/2025, with an aggregate market value of $10,552.15. The filer acquired these shares as restricted stock on 09/02/2025 as compensation. The filing also discloses two restricted stock sales by the same person in the past three months: 3,255 shares sold on 06/02/2025 for $11,831.27 and 6,057 shares sold on 06/05/2025 for $23,890.63. The filing includes the standard representation that the seller is not aware of undisclosed material adverse information.
FAQ
What is the current stock price of Health Catalyst (HCAT)?
What is the market cap of Health Catalyst (HCAT)?
